Download the White Paper

IntegriCell™ Standardizing Cryopreservation for a Sustainable Cell Therapy Supply Chain

Explore how IntegriCell™ cryopreservation services mitigates risks associated with the supply and transportation of critical starting materials.

This white paper addresses the challenges associated with utilizing fresh materials and provides an innovative approach to delivering high-quality, consistent cryopreserved leukapheresis commonly used as starting materials for many cell-based therapies.  The IntegriCell™ automated closed process (ACP) for cryopreservation incorporates several critical steps to ensure high-quality preservation of leukapheresis materials, including:

• Leukapheresis Transport – Supports the transportation of leukapheresis from collection centers to our cryopreservation sites.
• Cryopreservation Process – IntegriCell™ applies a standardized cryopreservation process of fresh leukapheresis within an ideal 24 hours of collection, coupled with rigorous quality control measures to ensure cell potency and viability.
• Storage and Distribution – IntegriCell™ features an integrated storage and distribution network that ensures controlled, worldwide transportation of the cryopreserved cells to their manufacturing destination.

Discover how you can leverage our IntegriCell™ solutions to minimize contamination risks, enhance reproducibility and consistency, and maintain superior quality.